September 21, 2021
Earlier this summer, we published a series of articles on the need to utilize weighting and prioritization tools in the...
Read article
August 13, 2021
With the cloud computing power that we have today, we can run simulation of 1000s of designs with each design...
Read article
August 9, 2021
Recently we discussed examining clinical development through a Bayesian lens, in honor of Cytel co-founder Nitin Patel...
Read article
May 14, 2021
When developing clinical strategy, applying familiar business principles to the specific requirements of clinical...
Read article
May 7, 2021
When is a study design considered to be optimal? A good design performs well not only under the ideal target scenario...
Read article
April 28, 2021
Recently, Cytel co-founder Professor Cyrus Mehta noted that, “Clinical trial design selection is too much like an art,...
Read article
April 20, 2021
For much of the past three decades, even as methodologies for clinical trial design have advanced and refined, the idea...
Read article
March 19, 2021
The use of wearable and digital technology requires considerations for both drugs and devices regulations, and...
Read article
March 18, 2021
Over the past ten years High-Performance Computing (HPC) has transformed medical research through advances in genomics,...
Read article
March 12, 2021
With wearables likely to become a regular part of clinical trial design, statisticians could benefit by familiarizing...
Read article
March 11, 2021
In the recent years, Oncology trials are seeing a technological shift that is expected to make them faster and more...
Read article
March 5, 2021
Early stage Phase 2 clinical trials are often designed as multi-stage single arm trials, which quickly identify...
Read article
February 26, 2021
In the world of clinical trials, the pace of innovation is accelerating, and approaches such as Bayesian methods are...
Read article
February 25, 2021
The convergence of several distinct trends has made wearables an increasingly attractive option for use in confirmatory...
Read article
February 19, 2021
C-Suite and R&D Decision-Makers are always striving to make evidence-driven decisions. Yet the rules by which evidence...
Read article
February 18, 2021
In the last few years, there has been a growing interest in historical borrowing or augmented trials. There is an...
Read article
February 12, 2021
In recent times, Single arm trials are being increasingly used to assess new treatment interventions. They establish...
Read article
February 11, 2021
The past two years have witnessed a heightened interest in the use of wearables in clinical development. The unexpected...
Read article
February 2, 2021
As the use of master protocols becomes more prevalent in drug development, Bayesian methods are extensively used to...
Read article
January 26, 2021
Bayesian models offer a flexible way of incorporating historical controls in the analysis of trial data (whether single...
Read article
January 22, 2021
COVID-19 has transformed the pharmaceutical industry in a manner that few could have predicted only a year ago. One of...
Read article
December 16, 2020
As we prepare to close the door on 2020, we asked Pantelis Vlachos, Principal/Strategic Consultant for Cytel, to share...
Read article
December 15, 2020
When designing clinical trials, biostatisticians and clinical development teams are often faced with a conundrum. Given...
Read article
December 9, 2020
As a part of Cytel’s Advanced Design Framework, a new Framework for the statistical design of clinical trials, Cytel...
Read article
December 3, 2020
Increasing Clinical Development Productivity Using Statistics and Cloud-Computing The need for Re-imagining Clinical...
Read article
November 24, 2020
Virtual ISPOR 2020, held November 16 to 19, presented new opportunities for scientific interaction amongst HEOR...
Read article
November 18, 2020
The current state of the clinical trials industry faces a challenge that was only hypothetical three or four years ago....
Read article
November 16, 2020
MUCE is a Bayesian solution for cohort expansion trials where multiple dose(s) and multiple indication(s) are tested in...
Read article
November 12, 2020
Cytel and Ingress Health (now a Cytel company) will be contributing to a range of events at Virtual ISPOR EUROPE 2020,...
Read article
November 11, 2020
The widespread use of cloud-computing has altered the clinical trial design process. Whereas three or four years ago,...
Read article
November 5, 2020
In oncology, many manufacturers go into niche indications, where there are very specific tumors, and then they opt for...
Read article
November 4, 2020
Cytel has recently revealed its Advanced Design Framework, a method developed by Cytel’s thought leaders that draws on...
Read article
October 29, 2020
Cytel has recently revealed its Advanced Design Framework, a method developed by Cytel’s thought leaders that draws on...
Read article
October 27, 2020
Cytel recently conducted a webinar on Bayesian Dose-finding Designs for Modern Drug Development, presented by Dr. Yuan...
Read article
October 26, 2020
Pharmaceutical and biotech companies are under pressure to deliver more and deliver faster with fewer resources. The...
Read article
October 23, 2020
Cytel’s New Horizons Webinar Series introduces you to the latest innovations in statistical trial design. This webinar...
Read article
October 22, 2020
In this two-part blog series, we interview Bart Heeg, Vice President HEOR and Founder at Ingress Health (A Cytel...
Read article
October 21, 2020
Cytel has recently revealed its Advanced Design Framework, a method developed by Cytel’s thought-leaders after a decade...
Read article
October 20, 2020
In this interview with Thomas Wilke, Principal Scientist at Ingress-Health (a Cytel company), we talk to him about his...
Read article
October 19, 2020
COVID-19 has created extreme uncertainties -- a dearth of historical information combined with the need for safety,...
Read article
October 15, 2020
For over a decade, advanced trial design techniques have promised efficient trials with accelerated timelines,...
Read article
October 14, 2020
A credible evidence base is needed to support and document the economic value of new technologies and therapeutic...
Read article
October 13, 2020
The combination of greater access to electronic health records, bigger electronic claims datasets, and the need for...
Read article
October 12, 2020
Cytel and Novartis are together hosting a complimentary Bayesian Virtual Symposium and an Interactive 7-part workshop....
Read article
October 7, 2020
With the rise in digital technologies, there has been an explosion in the volume and type of data sources. We can...
Read article
October 1, 2020
Methods involving Group Sequential Designs are one of the earliest deviations from a traditional two-arm clinical trial...
Read article
September 29, 2020
Innovation in trial designs are offering new routes forward for organizations of any size. They are now also aligned...
Read article
September 25, 2020
Regulators in both the United States and Europe have responded positively to the use of synthetic control arms (SCA)s...
Read article
September 17, 2020
Keeping up with the rapid pace of clinical development means that we need to adopt the innovative or computationally...
Read article
September 16, 2020
Synthetic control arms (SCA) are virtual trial arms that use historical claims data and observational data to simulate...
Read article
September 9, 2020
Cytel’s co-founder, Nitin Patel, conducted a webinar on designing clinical trials from a program-level perspective. His...
Read article
August 31, 2020
Pantelis Vlachos, Principal, Strategic Consultant at Cytel, conducted a webinar to introduce the capabilities of East...
Read article
August 25, 2020
It is important to take a strategic approach to clinical development in order to minimize the potential for Phase 3...
Read article
August 11, 2020
While there is increasing optimism about the discovery of a COVID-19 vaccine, one of the less talked about aspects of...
Read article
August 4, 2020
Last year, Paul Terrill, Associate Principal of Strategic Consulting at Cytel, presented an engaging webinar on the...
Read article
July 22, 2020
Cytel brings to you a new blog series on technology and Bayesian decision-making by Pantelis Vlachos,...
Read article
July 13, 2020
Cytel is hosting a complimentary webinar series that introduces biostatisticians and other members of the development...
Read article
June 10, 2020
Cytel is conducting a webinar series that introduces biostatisticians to some of the more commonly used complex...
Read article
May 27, 2020
In this blog, we speak with Christopher Jennison, Professor of Statistics at the University of Bath, UK. Professor...
Read article
May 5, 2020
Cytel's team of oncology trial design and advanced analytics experts are hosting a series of complimentary webinars...
Read article
April 23, 2020
Cytel is hosting a webinar, “A Clinician’s Perspective on Cancer Drugs Development”, on April 28, 2020. Our speaker,...
Read article
March 5, 2020
Generating high-quality clinical data is a vital but challenging task in modern drug development. Unfortunately, in the...
Read article
January 22, 2020
In the quest for clinical success, we all strive for evidence packages of the highest quality. If the clinical data is...
Read article
January 8, 2020
In clinical development, data is the vital ‘foundation’ that supports your programs. To successfully bring a promising...
Read article
November 5, 2019
Cytel is delighted to have Kannan Natarajan speaking at the “Complex Innovative Trial Design Symposium and East User...
Read article
October 10, 2019
A disease is generally considered to be rare if it affects one patient per 200,000 people (1) and most rare diseases...
Read article
November 12, 2018
In this blog, we talk with Robert Greene, Founder and President of the HungerNDThirst Foundation, about his upcoming...
Read article
October 5, 2018
We are delighted that Stephen Senn will be joining us at the EUGM on November 14th and 15th in Darmstadt, Germany. In...
Read article
September 27, 2018
In this blog, we talk with Heiko Götte, Senior Expert Biostatistician at Merck about his upcoming presentation at...
Read article
August 15, 2018
Cytel’s 7th East User Group Meeting (EUGM) will take place on November 14 & 15, 2018 at Merck in Darmstadt, Germany,...
Read article
July 3, 2018
It’s shaping up to be a busy year for Cytel’s software development team with a number of upgrades and planned launches...
Read article
February 27, 2018
We extend our congratulations to Lipopharma and the CLINGLIO project consortium on their recent 6,15M€ grant award by...
Read article
October 31, 2017
As part of Cytel's new Trial Innovations Webinar Series, Pat Mitchell, Statistical Science Director at AstraZeneca...
Read article
October 18, 2017
Cytel's new Trial Innovations Webinar Series provides a platform for the most promising new statistical approaches...
Read article
June 8, 2017
Cytel's Madhusmita Panda presented at this year’s PSI Conference in the Innovative Methodology session on the topic of...
Read article
December 4, 2014
Fulyzaq® from Napo/Salix was the first drug ever to be approved using an adaptive two-stage "seamless" clinical trial...
Read article
November 6, 2014
Professor LJ Wei holds that rules are for lawyers, not (necessarily) clinicians. When designing modern clinical trials,...
Read article
October 2, 2014
Sofia S. Villar is a member of the DART (Design and Analysis of Randomised Trials) group at the MRC Biostatistics Unit...
Read article
September 2, 2014
As more clinical trials make use of adaptive designs, investors have come to realize that high quality trial designs...
Read article
August 26, 2014
During an invited speakers session at the lnternational Society for Clinical Biostatistics, Cytel VP Yannis Jemiai was...
Read article
August 12, 2014
Beyond Wild Horses: Developing Innovation at Cytel "Horse-and-pony" by arjecahn on flickr. -...
Read article
July 17, 2014
In anticipation of Cyrus Mehta’s webinar next week on new predictive analytics tools for trial forecasting, we thought...
Read article
April 24, 2014
Here at Cytel we firmly believe that if you don’t get the design of a clinical program right, then nothing else...
Read article
